Health Catalyst (NASDAQ:HCAT) Given New $6.00 Price Target at Royal Bank of Canada

Health Catalyst (NASDAQ:HCAT) had its price objective decreased by Royal Bank of Canada from $7.00 to $6.00 in a research report sent to investors on Thursday,Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock.

Other analysts have also recently issued reports about the stock. Wells Fargo & Company lowered their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler decreased their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. Stephens reissued an “equal weight” rating and set a $7.00 price objective on shares of Health Catalyst in a research note on Thursday. Canaccord Genuity Group reduced their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Finally, KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.45.

Health Catalyst Trading Down 13.0 %

Shares of HCAT opened at $4.30 on Thursday. The business’s 50-day moving average price is $6.03 and its 200-day moving average price is $7.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a twelve month low of $3.76 and a twelve month high of $9.24. The stock has a market cap of $261.46 million, a PE ratio of -3.18 and a beta of 1.34.

Insider Buying and Selling at Health Catalyst

In related news, General Counsel Benjamin Landry sold 19,268 shares of Health Catalyst stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now owns 72,250 shares in the company, valued at $601,120. This trade represents a 21.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the sale, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 87,610 shares of company stock worth $664,043 over the last ninety days. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in Health Catalyst during the 4th quarter valued at about $29,000. Group One Trading LLC lifted its position in Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after purchasing an additional 2,260 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $34,000. Aquatic Capital Management LLC bought a new position in shares of Health Catalyst in the fourth quarter worth approximately $63,000. Finally, Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst in the fourth quarter worth $77,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.